AstraZeneca (AZN)
92.77
0.00 (0.00%)
Upcoming Events
Latest Headlines
AstraZeneca reports positive SERENA-6 trial results for camizestrant
June 2, 2026 8:02 AM - StreetInsider
Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6
June 2, 2026 8:00 AM - BizWire
Form 6-K ASTRAZENECA PLC For: Jun 01
June 1, 2026 10:10 AM - SEC Filing
Form 6-K ASTRAZENECA PLC For: Jun 01
June 1, 2026 10:06 AM - SEC Filing
AstraZeneca IMFINZI combo cuts liver cancer progression risk by 30%
June 1, 2026 8:01 AM - StreetInsider
IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in
June 1, 2026 8:00 AM - BizWire
Form 6-K ASTRAZENECA PLC For: May 29
May 29, 2026 6:44 AM - SEC Filing
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
May 28, 2026 9:18 PM - BizWire
Form 25-NSE ASTRAZENECA PLC Filed by: NEW YORK STOCK EXCHANGE LLC
May 28, 2026 2:29 PM - SEC Filing
FDA Approves Durvalumab in Combination with Bacillus Calmette-Guerin for High-Risk Non-Muscle Invasive Bladder Cancer
May 28, 2026 12:42 PM - StreetInsider
Form 6-K ASTRAZENECA PLC For: May 27
May 27, 2026 6:05 AM - SEC Filing
FDA extends review period for AstraZeneca breast cancer drug camizestrant
May 27, 2026 4:04 AM - StreetInsider
Form 6-K ASTRAZENECA PLC For: May 26
May 26, 2026 7:17 AM - SEC Filing
Form 6-K ASTRAZENECA PLC For: May 26
May 26, 2026 7:10 AM - SEC Filing
Form 6-K ASTRAZENECA PLC For: May 26
May 26, 2026 7:02 AM - SEC Filing
Form 4 ASTRAZENECA PLC For: May 20 Filed by: Sharma Mani
May 22, 2026 4:06 PM - SEC Filing
DATROWAY approved in US for first-line metastatic triple-negative breast cancer
May 22, 2026 10:17 AM - StreetInsider
DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple-negative breast cancer who are not
May 22, 2026 10:16 AM - BizWire
Daiichi Sankyo gets US approval for Datroway in metastatic breast cancer
May 22, 2026 9:30 AM - StreetInsider
Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Cand
May 22, 2026 9:30 AM - BizWire
Enhertu gets EU panel backing for HER2 positive metastatic solid tumors
May 22, 2026 8:00 AM - StreetInsider
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors
May 22, 2026 8:00 AM - BizWire
AstraZeneca's camizestrant wins EU panel backing for breast cancer
May 22, 2026 7:30 AM - StreetInsider
AstraZeneca to present Phase III cancer data at ASCO 2026
May 22, 2026 7:00 AM - StreetInsider
AstraZeneca to showcase Phase III data in liver, breast and bladder cancers and potential first-in-class rare disease therapy at ASCO 2026
May 22, 2026 7:00 AM - BizWire
Trump to unveil more discounted prescription drug options - CNBC
May 18, 2026 10:59 AM - StreetInsider
Form 6-K ASTRAZENECA PLC For: May 18
May 18, 2026 10:16 AM - SEC Filing
Form 6-K ASTRAZENECA PLC For: May 18
May 18, 2026 9:42 AM - SEC Filing
Form 6-K ASTRAZENECA PLC For: May 18
May 18, 2026 9:36 AM - SEC Filing
AstraZeneca's BAXFENDY wins FDA approval for resistant hypertension
May 18, 2026 7:00 AM - StreetInsider
BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension
May 18, 2026 7:00 AM - BizWire
AstraZeneca receives FDA approval for hypertension drug Baxfendy
May 18, 2026 5:07 AM - StreetInsider
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for two new indications for patients with HER2-positive early breast cancer
May 15, 2026 9:52 PM - BizWire
Enhertu® Approved in the U.S. for Two New Indications for Patients with HER2 Positive Early Breast Cancer
May 15, 2026 6:31 PM - BizWire
Form 6-K ASTRAZENECA PLC For: May 14
May 14, 2026 7:25 AM - SEC Filing
Perioperative IMFINZI® (durvalumab) plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder
May 14, 2026 7:00 AM - BizWire
AstraZeneca drug combo shows survival benefit in bladder cancer trial
May 14, 2026 5:52 AM - StreetInsider
AstraZeneca drug meets primary endpoint in rare disease trial
May 12, 2026 6:53 AM - StreetInsider
Form 4 ASTRAZENECA PLC For: Apr 07 Filed by: Sharma Mani
May 8, 2026 4:06 PM - SEC Filing
Health officials explore restrictions on certain SSRI antidepressants - Reuters
May 8, 2026 12:04 PM - StreetInsider
Form 6-K ASTRAZENECA PLC For: May 01
May 1, 2026 10:24 AM - SEC Filing
Form 6-K ASTRAZENECA PLC For: May 01
May 1, 2026 9:15 AM - SEC Filing
Form 6-K ASTRAZENECA PLC For: May 01
May 1, 2026 9:12 AM - SEC Filing
AstraZeneca slips after FDA panel rejects breast cancer drug camizestrant
May 1, 2026 5:49 AM - StreetInsider
FDA Advisory Committee recommends TRUQAP for prostate cancer subtype
May 1, 2026 5:44 AM - StreetInsider
TRUQAP® (capivasertib) recommended by FDA Advisory Committee for PTEN-deficient metastatic hormone-sensitive prostate cancer
April 30, 2026 9:42 PM - BizWire
FDA Panel Votes 6-3 'no' On Astrazeneca Breast Cancer Drug
April 30, 2026 11:49 AM - StreetInsider
Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca
April 29, 2026 7:00 PM - PR NewsWire
Form 6-K ASTRAZENECA PLC For: Apr 29
April 29, 2026 7:23 AM - SEC Filing
AstraZeneca results: Q1 2026
April 29, 2026 7:00 AM - BizWire
AstraZeneca tops Q1 forecasts on strong cancer, rare-disease drug demand
April 29, 2026 6:09 AM - StreetInsider
AstraZeneca (AZN) Tops Q1 EPS by 6c; offers guidance
April 29, 2026 3:23 AM - StreetInsider
AstraZeneca Q1 preview: In-line quarter expected as pipeline catalysts take center stage
April 28, 2026 4:00 PM - StreetInsider
AstraZeneca, Amgen partner with FDA to test real-time AI trial monitoring
April 28, 2026 1:46 PM - StreetInsider
Form SCHEDULE 13G ASTRAZENECA PLC Filed by: VANGUARD CAPITAL MANAGEMENT LLC
April 28, 2026 11:33 AM - SEC Filing
Form 6-K ASTRAZENECA PLC For: Apr 28
April 28, 2026 7:32 AM - SEC Filing
AstraZeneca's BREZTRI wins US approval for asthma treatment
April 28, 2026 7:03 AM - StreetInsider
BREZTRI approved in the US for asthma as first and only triple therapy for patients 12 years of age and older
April 28, 2026 7:00 AM - BizWire
AstraZeneca wins FDA approval for SAPHNELO autoinjector pen for lupus
April 27, 2026 7:03 AM - StreetInsider
SAPHNELO approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus
April 27, 2026 7:00 AM - BizWire
Form 6-K ASTRAZENECA PLC For: Apr 27
April 27, 2026 6:29 AM - SEC Filing
Form 6-K ASTRAZENECA PLC For: Apr 23
April 23, 2026 6:10 AM - SEC Filing
Form 6-K ASTRAZENECA PLC For: Apr 21
April 21, 2026 6:19 AM - SEC Filing
Form 6-K ASTRAZENECA PLC For: Apr 20
April 20, 2026 7:04 AM - SEC Filing
AstraZeneca's tozorakimab meets primary endpoint in Phase III COPD trial
April 20, 2026 7:01 AM - StreetInsider
Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD
April 20, 2026 7:00 AM - BizWire
AstraZeneca reports positive Phase III trial results for COPD drug
April 20, 2026 6:07 AM - StreetInsider
AstraZeneca (AZN:LN) (AZN) PT Raised to GBp180 at Citi
April 10, 2026 5:23 AM - StreetInsider
Form 6-K ASTRAZENECA PLC For: Apr 09
April 9, 2026 1:02 PM - SEC Filing
Form 25-NSE ASTRAZENECA PLC Filed by: NEW YORK STOCK EXCHANGE LLC
April 8, 2026 2:21 PM - SEC Filing
AstraZeneca (AZN) PT Raised to $220 at Morgan Stanley
April 7, 2026 2:40 PM - StreetInsider
AstraZeneca (AZN:LN) (AZN) PT Raised to GBp16,500 at Morgan Stanley
April 7, 2026 2:38 PM - StreetInsider
FDA approves multiple generics of Farxiga
April 7, 2026 2:06 PM - StreetInsider
Form 6-K ASTRAZENECA PLC For: Apr 02
April 2, 2026 9:27 AM - SEC Filing
AstraZeneca's IMFINZI and IMJUDO combination shows progression benefit in liver cancer
April 2, 2026 7:00 AM - StreetInsider
IMFINZI® (durvalumab) + IMJUDO® (tremelimumab-actl) improves PFS in early liver cancer
April 2, 2026 7:00 AM - BizWire
Form 6-K ASTRAZENECA PLC For: Apr 01
April 1, 2026 10:30 AM - SEC Filing
AstraZeneca (AZN) call put ratio 1.2 calls to 1 put as share price up 5%
March 31, 2026 1:55 PM - StreetInsider
AstraZeneca (AZN) 6K contracts of April 220 calls trade
March 31, 2026 1:50 PM - StreetInsider
Form 6-K ASTRAZENECA PLC For: Mar 31
March 31, 2026 7:48 AM - SEC Filing
AstraZeneca reports mixed results for HPP drug efzimfotase alfa
March 31, 2026 3:34 AM - StreetInsider
TD Cowen Reiterates Buy Rating on AstraZeneca (AZN) Amid Potential 'Multi-Billion $ Opportunity'
March 30, 2026 8:36 AM - StreetInsider
Deutsche Bank Reiterates Sell Rating on AstraZeneca (AZN:LN) (AZN)
March 30, 2026 4:29 AM - StreetInsider
AstraZeneca (AZN) PT Raised to $220 at Leerink Partners
March 27, 2026 4:33 PM - StreetInsider
Form 6-K ASTRAZENECA PLC For: Mar 27
March 27, 2026 8:05 AM - SEC Filing
AstraZeneca drug meets goals in two COPD trials
March 27, 2026 7:01 AM - StreetInsider
Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD
March 27, 2026 7:00 AM - BizWire
Advancements in Novel Immunotherapeutics in The Oncology Battle
March 24, 2026 10:32 AM - StreetInsider
Form 6-K ASTRAZENECA PLC For: Mar 20
March 20, 2026 8:00 AM - SEC Filing
These are the best EU pharma stocks to buy: analyst
March 20, 2026 6:00 AM - StreetInsider
Form 3 ASTRAZENECA PLC For: Mar 18 Filed by: Sharma Mani
March 19, 2026 7:52 PM - SEC Filing
TD Cowen: 'AstraZeneca's (AZN) history of innovation offers opportunity for upside'
March 18, 2026 9:24 AM - StreetInsider
Form 6-K ASTRAZENECA PLC For: Mar 16
March 16, 2026 8:46 AM - SEC Filing
AstraZeneca and Joshua Jackson partner to encourage fans to Get Body Checked Against Cancer
March 10, 2026 8:30 AM - BizWire
Form 6-K ASTRAZENECA PLC For: Mar 10
March 10, 2026 8:10 AM - SEC Filing
Form 6-K ASTRAZENECA PLC For: Mar 10
March 10, 2026 7:38 AM - SEC Filing
AstraZeneca (AZN:LN) (AZN) PT Raised to GBP160 at Guggenheim
March 10, 2026 6:07 AM - StreetInsider
ENHERTU receives priority review for HER2-positive early breast cancer
March 9, 2026 8:45 AM - StreetInsider
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US as post-neoadjuvant treatment for patients with HER2-positive early breast cancer
March 9, 2026 7:00 AM - BizWire
ENHERTU® Granted Priority Review in the U.S. as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer
March 9, 2026 2:30 AM - BizWire
Full Article List
